Natural history of changes in prostate specific antigen in early stage prostate cancer.

[1]  H. Carter,et al.  Mixed-effects regression models for studying the natural history of prostate disease. , 1994, Statistics in medicine.

[2]  J. Cadeddu,et al.  Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. , 1993, Urology.

[3]  T. Stamey,et al.  Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.

[4]  P. Carroll,et al.  Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. , 1993, The Journal of urology.

[5]  D. Chan,et al.  Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. , 1992, Cancer research.

[6]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[7]  L. Holmberg,et al.  High 10-year survival rate in patients with early, untreated prostatic cancer. , 1992, JAMA.

[8]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[9]  S. Clejan,et al.  Prostate specific antigen and prostatitis I. Effect of prostatitis on serum psa in the human and nonhuman primate , 1992, The Prostate.

[10]  A. Whittemore,et al.  Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? , 1991, Journal of the National Cancer Institute.

[11]  J. Adolfsson,et al.  Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old. , 1991, The Journal of urology.

[12]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[13]  I. Thompson,et al.  Expectant management of localized prostatic cancer , 1991, Cancer.

[14]  D. Chan,et al.  The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. , 1990, The Journal of urology.

[15]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[16]  J. McNeal,et al.  Pathology of benign prostatic hyperplasia. Insight into etiology. , 1990, The Urologic clinics of North America.

[17]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[18]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[19]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. , 1989, The Journal of urology.

[20]  H. Adami,et al.  NATURAL HISTORY OF LOCALISED PROSTATIC CANCER A Population-based Study in 223 Untreated Patients , 1989, The Lancet.

[21]  J. Oesterling,et al.  The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. , 1989, The Journal of urology.

[22]  A. Partin,et al.  Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. , 1989, The Journal of urology.

[23]  N. Juul,et al.  Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. , 1988, Scandinavian journal of urology and nephrology. Supplementum.

[24]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[25]  T. Stamey,et al.  PATTERNS OF PROGRESSION IN PROSTATE CANCER , 1986, The Lancet.

[26]  David Arenberg,et al.  Normal Human Aging: The Baltimore Longitudinal Study on Aging , 1984 .

[27]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[28]  J. Meyer,et al.  Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. , 1982, The Journal of urology.

[29]  D. S. Coffey,et al.  Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. , 1982, Cancer research.